AXIM BiotechnologiesAXIM +51.33% Return-on-Tangible-Asset is 636.56% as of Jun. 2025. The stock has 7 warning signs investors should review. Among 1,418 Biotechnology companies, AXIM Biotechnologies ranks better than 98.59% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. AXIM Biotechnologies's annualizedNet Income for the quarter that ended in Jun. 2025 was $1.48 Mil. AXIM Biotechnologies's average total tangible assets for the quarter that ended in Jun. 2025 was $0.23 Mil. Therefore, AXIM Biotechnologies's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2025 was 636.56%.
The historical rank and industry rank for AXIM Biotechnologies's Return-on-Tangible-Asset or its related term are showing as below:
AXIM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2149.33 Med: -688.63 Max: 52.26
Current: 52.26
During the past 13 years, AXIM Biotechnologies's highest Return-on-Tangible-Asset was 52.26%. The lowest was -2149.33%. And the median was -688.63%.
AXIM's Return-on-Tangible-Asset is ranked better than 98.59% of 1418
companies
in the Biotechnology industry
Industry Median: -35.915
vs AXIM: 52.26
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
AXIM Biotechnologies Return-on-Tangible-Asset Related Terms
AXIM Biotechnologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM vs ZVSA, HEPA, ISCO: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, AXIM Biotechnologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2025) net income data.
What does a Return-on-Tangible-Asset of 636.56% mean?
AXIM Biotechnologies (AXIM) has a Return-on-Tangible-Asset of 636.56% as of Jun. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #20 out of 1418 companies in the Biotechnology industry, placing it in the top 1.4%.
Is AXIM Biotechnologies' Return-on-Tangible-Asset too high?
AXIM Biotechnologies' current Return-on-Tangible-Asset is 636.56%. Based on the distribution chart, AXIM Biotechnologies ranks #20 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does AXIM Biotechnologies' Return-on-Tangible-Asset compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #20 out of 1418 companies for Return-on-Tangible-Asset. This places AXIM Biotechnologies in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Return-on-Tangible-Asset is 636.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Return-on-Tangible-Asset of 636.56%. The current Return-on-Tangible-Asset is 636.56%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Return-on-Tangible-Asset is 636.56% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 